Elevated C-Reactive Protein (CRP) during First-Trimester For Gestational Diabetes Screening

Sheema Yousuf
Department of Obstetrics and Gynaecology, Patel Hospital, Karachi, Pakistan.

ABSTRACT

Background: Studies investigating the impact of inflammatory factors on gestational diabetes mellitus (GDM) are extremely sparse. This study aimed to find out the association of inflammation as defined by C-reactive protein (CRP) with gestational diabetes.

Methods: This prospective cohort study, conducted in Patel Hospital Karachi from September 2020 to February 2021, enrolled 172 healthy gravid women at ≤ 10 weeks of pregnancy. A structured proforma was used to record age, education, past medical and obstetric history (parity, number of miscarriages, mode of deliveries, gestational age), blood pressure, height, and weight of all patients. Serum concentration of CRP and levels >1mg/dl was considered high. Oral glucose tolerance test was performed at 24-28 weeks to diagnose GDM. Data was analysed by using SPSS and Chi-squared test was applied to compare the difference between groups with, and without diabetes and p-value ≤ 0.05 was considered significant.

Results: Total 93 patients had raised CRP of which 8(4.6%) developed GDM (p<0.00001). Advanced age (p=0.00042) and weight (p<0.00001) were found to be independent risk factors. It was observed that CRP levels rise with increasing weight (p=0.0095) however, parity and blood pressure had no effect on GDM development. Women who had diabetes had higher BMI (<0.00001) showing that increasing weight was an independent risk factor. The sensitivity and specificity of CRP in detecting GDM was 100% and 48.17%.

Conclusion: Raised C-reactive protein levels in first trimester can lead to subsequent development of hyperglycaemia of pregnancy and thus can be considered as an easy and simple screening test for GDM.

Keywords: Gestational Diabetes Mellitus; C-Reactive Protein; Inflammation; Oral Glucose Tolerance Test.

INTRODUCTION

Gestational Diabetes Mellitus (GDM) is defined as hyperglycaemia that is first recognized in the second or third trimester of pregnancy in women with previous normal sugar levels and can lead to numerous adverse outcomes for mother and baby. GDM prevalence varies across the world affecting almost 7-10% of pregnancies worldwide. The sooner the disease is detected in pregnancy the better would be the outcome. Women who had a history of hyperglycaemia in pregnancy have an increased chance of getting adult onset diabetes later on in life.

Diabetes of pregnancy is more prevalent in women who are above 30 years, overweight or obese, have diabetes in family, previous history of stillbirth or anomalous baby and have gestational diabetes in the previous pregnancy. GDM screening tests are done after assessing risk factors. There is increase insulin resistance in pregnancy making it a
diabetogenic condition. Insulin resistance is linked with inflammatory conditions and the development of type 2 diabetes. It is shown by several studies that increased inflammation as measured by CRP is an independent risk factor for the development of diabetes.

Although pregnancy itself is an anti-inflammatory condition, there is an increased level of inflammation during the early stage of pregnancy such as during implantation leading to increasing levels of various inflammatory mediators. High maternal CRP is associated with miscarriage, premature labour and rupture of membranes, toxemia of pregnancy, fetal growth restriction and chorioamnionitis. The possible mechanism by which inflammation leading to diabetes could be the increase blood sugar and glycosylated haemoglobin levels (HbA1c) causing the release of CRP. In addition, obesity, which is a risk factor for GDM, causes an increase release of pro-inflammatory cytokines from adipocytes. Currently, it is being hypothesized systemic inflammation may be involved in the establishment of GDM. Early diagnosis and treatment are very crucial to prevent maternal and neonatal adverse outcome. Therefore, this study was performed to define the role of CRP in the screening of gestational diabetes.

**METHODS**

It was a prospective cohort study conducted from September 2020 until February 2021. A total number of 172 pregnant patients attending antenatal checkups in Department of Obstetrics and Gynaecology of Patel Hospital, Karachi were selected. All pregnant women 18-35 years with single fetus less than 10 weeks of gestation based on their last menstrual period were included in the study after written informed consent. All patients were ensured about the confidentiality of identity and were given free choice of withdrawing from the study at any point. Ethical approval was obtained from the institutional ethic committee (Ref no.102/2020).

A structured proforma was used to record age, education, past medical and obstetric history (parity, number of miscarriages, mode of deliveries, gestational age), blood pressure, height, and weight of all patients at booking. Patients with previous history of hyperglycaemia in pregnancy, pre-existing or family history of diabetes, random blood sugar (RBS) of more than 140mg/dl, history of macrosomia, stillbirth, recurrent miscarriage, hypertension and polycystic ovarian syndrome were excluded from the study. Patients with chronic hypertension, thyroid disorder, chronic kidney disease, cardiovascular disease, autoimmune and chronic inflammatory disease, current active infection, antibiotic use within two weeks before sampling, seasonal allergy and those taking corticosteroids or non-steroidal anti-inflammatory drugs were also excluded.

The blood sample was taken for serum CRP in addition to the standard antenatal tests from all patients in the first trimester. Participants were followed up until 24-28 week of pregnancy and 75g oral glucose tolerance test (OGTT) was carried out at that time. CRP level was measured by latex agglutination semi-quantitative test kit. CRP > 1mg/dl was considered raised. Gestational diabetes was diagnosed by Hyperglycaemia and Adverse Pregnancy Outcome (HAPO) criteria (fasting blood glucose ≥ 92mg/dl, 1-hour ≥ 180mg/dl, 2-hour ≥ 153mg/dl).

Data were analyzed by using SPSS version 22. Mean, standard deviation and frequency table was used for data presentation. Chi-square test was used to compare the difference between groups with and without diabetes. The 2 × 2 contingency table was used for calculating sensitivity, specificity, positive predictive value, negative predictive value and accuracy. The level of significance was kept at p-value ≤ 0.05.

**RESULTS**

The average age of patients was 26.5±5.33 years and mean gestation of pregnancy was 7.5±1.87 weeks. The majority of participants were multipara (74.41%), educated (72.6%) and working women (76.1%). The average body mass index was 24.03±3.83 kg/m². The mean random blood sugar was 99.5±22.7mg/dl. The association of CRP and GDM with baseline characteristics is shown in Table 1.
Out of 172 patients, ninety-three had raised CRP of which 8(8.6%) developed GDM (p<0.00001) showing a significant association between high serum C reactive protein and gestational diabetes as shown in Figure 1. It is shown in Table 2 that with increasing levels of CRP the risk of GDM also increases.

Table 1: Association of C-reactive protein (CRP) and gestational diabetes (GDM) with age, parity, gestation, BMI, blood pressure and random blood sugar.

| Variables           | CRP ≤1mg/d | CRP >1mg/dl | p-Value | GDM   | p-Value |
|---------------------|------------|--------------|---------|-------|---------|
| **Age in years**    |            |              |         |       |         |
| 18-24               | 20(44.44%) | 25 (55.55%) | 0.75    | 01(2.22%) | 0.00042 |
| 25-30               | 42(41.17%) | 60(58.82%)  | 02(1.96%) |       |         |
| 31-35               | 12(48%)    | 13(52%)     | 05(20%) |       |         |
| **Gestational age in weeks** |            |              |         |       |         |
| 5-6                 | 21(45.65%) | 25(54.34%)  | 0.98    | - |         |
| 7-10                | 58(46.03%) | 68(53.96%)  | -       |       |         |
| Nullipara           | 19(43.18%) | 25(56.81%)  | 0.91    | 2(4.54%) | 0.99    |
| Multipara           | 60(46.87%) | 68(53.12%)  | 6(4.68%) |       |         |
| **BMI in kg/m²**    |            |              |         |       |         |
| <18.5-24.9          | 49(57.64%) | 36(42.35%)  | 0.0095  | 0 | <0.00001 |
| 25-29.9             | 25(34.72%) | 47(65.27%)  | 3(4.16%) |       |         |
| ≥30                 | 5(33.33%)  | 10(66.66%)  | 5(33.33%) |       |         |
| **Systolic blood pressure in mmHg** |            |              |         |       |         |
| 100-120             | 67(44.66%) | 83(55.33%)  | 0.53    | 6(4%)  | 0.10    |
| 121-139             | 12(54.54%) | 10(45.45%)  | 2(9.09%) |       |         |
| **Random blood sugar in mg/dl** |            |              |         |       |         |
| <120                | 44(46.80%) | 50(53.19%)  | 0.79    | 0 | 0.0014  |
| 120-139             | 35(44.87%) | 43(55.12%)  | 8(10.25%) |       |         |

BMI: body mass index, GDM: gestational diabetes, BP: Blood pressure.
Elevated C-Reactive Protein (CRP) during First-Trimester For Gestational Diabetes Screening

Table 2: Comparison of C-reactive protein (CRP) levels and gestational diabetes (GDM).

| Quantitative CRP mg/dl | GDM   | Without GDM | p-Value |
|-------------------------|-------|-------------|---------|
| ≤1                      | 00    | 79 (100%)   | <0.00001|
| 2-4                     | 00    | 67 (100%)   |         |
| 5-10                    | 02 (11.11%) | 16 (88.88%)|         |
| >10                     | 06 (75%) | 02 (25%)   |         |

| C-reactive protein     | GDM   | Without GDM | Total  |
|------------------------|-------|-------------|--------|
| Positive CRP           | 08 (TP)| 85 (FP)     | 93 (54.06%) |
| Negative CRP           | 0 (FN)| 79 (TN)     | 79 (45.9%) |
| Total                  | 08 (4.65%) | 164 (95.34%) |        |

It was found that CRP levels rise with increasing weight (p=0.0095) indicating that CRP level is independently related to BMI which can be seen in Figure 2. The risk of GDM increased with advance maternal age (p=0.00042). However, parity and blood pressure had no effect on GDM development. It was also found in our study that women who had diabetes were of higher Body mass index (BMI) (<0.00001) Table 1. Thus, it was showing that increasing weight was an independent risk factor for GDM as shown in Figure 2.

![Association of BMI with CRP and GDM](https://doi.org/10.36283/PJMD10-4/005)

**Figure 2:** Association of body mass index (BMI) with C-reactive protein (CRP) levels and gestational diabetes (GDM).

The sensitivity, specificity, positive predictive value, negative predictive value and accuracy of CRP in detecting GDM was 100%, 48.17%, 8.6%, 100% and 50.58% respectively as shown in Table 3.

Table 3: Accuracy of C-reactive protein (CRP) as a screening test for gestational diabetes (GDM).

| Statistic          | Value       | 95% CI       |
|--------------------|-------------|--------------|
| Sensitivity        | 100%        | 63.06 - 100  |
| Specificity        | 48.17%      | 40.31 - 56.10|
| PPV                | 8.60%       | 7.51 - 9.84  |
| NPV                | 100%        | -            |
| Accuracy           | 50.58%      | 42.87-58.28  |
| Positive likelihood ratio | 1.93      | 1.66 -2.24   |
| Negative likelihood ratio | 0.00      | -            |

PPV: Positive Predictive Value, NPV: Negative Predictive Value, CI: Confidence Interval.
**DISCUSSION**

In a current study out of ninety-three patients with raised CRP, 8(8.6%) developed GDM (p=0.00001) showing that high C-reactive protein can result in GDM. This is inconsistency with previous research studies13,14. Increased levels of CRP in the blood can lead to hyperglycaemia by influencing insulin resistance15. It has been shown in others studies that elevated CRP levels in blood have a notable relation with subsequent development of hyperglycaemia of pregnancy16. Patients with gestational diabetes tend to have higher CRP levels as compared to normal pregnant women14. Hence, quantitative C-reactive protein level is an acceptable test in predicting diabetes in pregnancy17. In contrast to the above, the studies by Corcoran and Korkmazer showed no association between CRP and GDM18,19.

Despite many researches, there is no general agreement on screening of gestational diabetes and the diagnostic threshold for glucose challenge test (GCT) varies. Furthermore, the tests used for screening diabetes in the first trimester involve drinking glucose solution that can cause nausea, sweaty or light-headedness1. A research study by Cunningham et al. showed that the sensitivity and specificity of GCT in GDM screening varies with glucose thresholds such as 80% and 82-86% while 90% and 75-80% when kept at 130mg/dl13. Whereas Farghaly et al. reported that CRP has a sensitivity and specificity of 86.49% and 98.47% respectively in detecting GDM13. The current study showed 100% sensitivity and 48.17% specificity of CRP in detecting GDM thus making it a good screening test for GDM owing to the very high sensitivity and simplicity of the test.

Gestational diabetes resolves spontaneously after delivery but is linked to complications in both mother and the newborn20. It has been proven that intrauterine exposure to maternal GDM can lead to glucose intolerance, obesity and type 2 diabetes in offspring21. Recently, there has been an increased interest to disclose the role of inflammation in GDM development. In a previous study, increased levels of CRP and IL-6 were observed in pregnant women with glucose intolerance and GDM. Thus, suggesting that these may have a role in the pathophysiology of glucose intolerance and can serve as potential serum markers for the early screening of glucose intolerance21. Furthermore, there is an elevated inflammatory response with increasing age and BMI and has a significant association with GDM and inflammatory response is observed with increases in both age and BMI22. Studies have suggested that there is strong correlation between body fat mass and serum CRP levels23. Obesity has been identified as a predictor of elevated CRP, which is a risk factor for cardiovascular and coronary heart disease24. Furthermore, C-reactive protein was highly correlated with body mass index in some previous research studies21. In the current study it was observed that patients with high BMI tend to have increased CRP levels (p=<0.0095) and there was a remarkable correlation between GDM and obesity (p=<0.00001).

Seeing that it is known that inflammation can cause diabetes in pregnancy by causing insulin resistance4. The increase in blood sugar levels accelerates the synthesis of glycosylated haemoglobin and the expression of macrophages thus causing the release of inflammatory markers like CRP10. CRP is a commonly available laboratory test and if combined with maternal risk factors as assessed by history and demographic features, can be predictive of GDM11. Thus, it helps in identification of those patients who are at higher risk of developing hyperglycaemia of pregnancy as early as in the first trimester. Recognizing these patients earlier can help in better maternal and neonatal outcomes by intervening through treatment and lifestyle modification.

However, a single measurement of serum CRP level does not provide a measure of maternal inflammation status. Besides, C reactive protein levels rise during normal pregnancy12. Further comprehensive studies are needed to assess diagnostic accuracy of serum CRP in GDM screening. In addition, inflammatory cytokine levels fluctuate throughout pregnancy. Therefore, the levels should be monitored multiple times for finding a specific correlation between inflammation and GDM or glucose intolerance.

**CONCLUSION**

Women with hyperglycaemia of pregnancy have increased inflammatory reactions during the first trimester. C reactive protein measurement could be a useful screening test in the first-trimester for the prediction of GDM. CRP test can be a new, fast and reliable screening test for GDM screening. However, further research studies are needed to strengthen these findings. It is easy to measure and can predict the risk of other pregnancy complications as well such as preeclampsia, preterm labour, intrauterine growth restriction etc. allowing better surveillance during gestation.

**AKNOWLEDGEMENTS**

Special thanks to Dr. Tashmina Taha and Dr. Durriya Rehmani for their help in sample collection.

**CONFLICT OF INTEREST**

There is no conflict of interest.

**ETHICS APPROVAL**

The ethical board of Patel Hospital (Ref no.102/2020) approved the following study.
PATIENTS' CONSENT

Verbal and written informed consents were obtained from all patients.

AUTHORS' CONTRIBUTION

SY was involved in randomization of patients, data collection and analysis, literature review, discussion, results and reference writing and authored the manuscript.

REFERENCES

1. American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2020. Diabetes Care. 2020;43(Supplement 1):S14-31.
2. Committee on Practice Bulletins—Obstetrics. ACOG practice bulletin No. 190: gestational diabetes mellitus. Obstet Gynecol. 2018;131(2):e49-64.
3. Ogurtsova K, da Rocha Fernandes J, Huang Y, Linnenkamp U, Guariqueta L, Cho N, et al. IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40-50.
4. Nguyen CL, Pham NM, Binns CW, Duong DV, Lee AH. Prevalence of gestational diabetes mellitus in eastern and South Eastern Asia: a systematic review and meta-analysis. J Diabetes Res. 2018;2018:1-10.
5. Adam S, Reeder P. Screening for gestational diabetes mellitus in a South African population: prevalence, comparison of diagnostic criteria and the role of risk factors. S Afr Med J. 2017;107:523-527.
6. Jackson SH, Bellatorre A, McNeel T, Nápoles AM, Choi K. Longitudinal associations between obesity, inflammation, and the incidence of type 2 diabetes mellitus among US black and white adults in the CARDIA study. J Diabetes Res. 2020;2020:1-10.
7. Mar G, Aldo P, Alvero AB. The unique immunological and microbial aspects of pregnancy. Nat Rev Immunol. 2017;17(8):469-482.
8. Nikbakht R, Moghadam EK, Nasirkhani Z. Maternal serum levels of C-reactive protein at early pregnancy to predict fetal growth restriction and preterm delivery: A prospective cohort study. Int J Reprod Biomed. 2020;18(3):157-164.
9. Vecchie A, Bonaventura A, Carbone F, Maggi D, Ferraiolo A, Carloni B, et al. C- Reactive protein levels at the mid-pregnancy can predict gestational complications. Biomed Res Int. 2018;2018:1-18.
10. Pan A, Wang Y, Yuan JM, Koh WP. High-sensitive C-reactive protein and risk of incident type 2 diabetes: a case–control study nested within the Singapore Chinese Health Study. BMC Endocr Disord. 2017;17(1):1-8.
11. Amirian A, Rahnemaei FA, Abdi F. Role of C-reactive Protein (CRP) or high-sensitivity CRP in predicting gestational diabetes mellitus: Systematic review. Diabetes Metab Syndr. 2020;14(3):229-236.
12. Miao ZR, Wu HH, Zhang YZ, Sun WJ, Lu DF, Yang HX, et al. Evaluation of the gestational diabetes mellitus diagnostic criteria recommended by the international association of diabetes and pregnancy study group for long-term maternal postpartum outcomes in mainland China. Medicine. 2020;99(8):1-6.
13. Farghaly TA, Helmy NA, Abbas AM, Ahmed AGM. C-reactive protein as a screening test for gestational diabetes mellitus in first-trimester of pregnancy: a prospective cohort study. Int J Reprod Contracept Obstet Gynecol. 2018;7(12):4798-4803.
14. Alamolhoda SH, Yazdikhasti M, Namdar M, Zakariayi SJ, Mirabi P. Association between C-reactive protein and gestational diabetes: a prospective study. J Obstet Gynaecol. 2020;40(3):349-353.
15. Haidari F, Jalali MT, Shahbazian N, Haghighizadeh MH, Azadegan E. Comparison of serum levels of vitamin D and inflammatory markers between women with gestational diabetes mellitus and healthy pregnant control. J Family Reprod Health. 2016;10(1):1-8.
16. Kumar R, Singh H. The prevalence of elevated high-sensitivity C-reactive protein in normal pregnancy and gestational diabetes mellitus. J Family Med Prim Care. 2017;6(2):259-264.
17. Ahí Z, Karlman N, Asl SZ, Shakeri N. Diagnostic cvalue of C-reactive protein in determining of gestational diabetes mellitus (GDM). Biosci Biotechnol Res Asia. 2016;13(2):743-750.
18. Corcoran S, Achamallah N, John OL, Graine K, Stafford P, Meaney S, et al. 739: Can first trimester high-sensitivity C-reactive protein and Sex Hormone Binding Globulin predict the onset of gestational diabetes? A prospective study of a high risk cohort. Am J Obstet Gynecol. 2016;214(1):5388.
19. Korkmazer E, Solak N. Correlation between inflammatory markers and insulin resistance in pregnancy. J Obstet Gynaecol. 2015;35:142-145.
20. Cunningham F, Leveno K, Bloom S, Spong CY, Dashe J, Williams Obstetrics, 24e. New York, NY, USA: Mcgraw-hill; 2014. 10 p.
21. Akhalya K, Sreelatha S, Rajeshwari KS. A review article-gestational diabetes mellitus. Endocrinol Metab Int J. 2019;7:26-39.
22. Shou C, Wei YM, Wang C, Yang HX. Updates in long-term maternal and Fetal adverse effects of gestational diabetes mellitus. Matern Fetal Med. 2019;1(2):91-94.
23. Zhao X, Liu J, Shen L, Wang A, Wang R. Correlation between inflammatory markers (hs-CRP, TNF-α, IL-1β, IL-6, IL-18), glucose intolerance, and gestational diabetes mellitus in pregnant women. Int J Clin Exp Med. 2018;11(8):8310-8316.
24. Schmidt FM, Wieschenfelder J, Sander C, Minkwitz J, Thomann J, Chittka T, et al. Inflammatory cytokines in general and central obesity and modulating effects of physical activity. PLoS One. 2015;10(3):1-17.
25. Paveal G, Kim YI, Salvy SJ. Additive effects of obesity and loneliness on C-reactive protein. PLoS One. 2018;13(11):1-10.